Biohaven meanwhile recorded Nurtec ODT sales of $462 million in 2021, a performance that prompted Pfizer to stump up $500 million upfront for rights to the drug outside the US last November.

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

A new report published in Brain Medicine reveals that a single dose of the drug Osanetant, administered shortly after a ...

The traditional film model for particle dissolution assumes that flux behavior depends primarily on particle size relative to ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

Getty Images Lepodisiran — an experimental drug made by the pharmaceutical company Eli Lilly — has been found to slash this type of cholesterol by nearly 94% after a single dose. Participants ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be untreatable, for up to one year. Lipoprotein(a) is a type of cholesterol ...

A new stroke thrombolytic — tenecteplase — marketed as TNKase — has received FDA approval, marking the first such advancement in nearly 30 years. Unlike alteplase (tPA), which requires a lengthy ...

such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT, that should help offset the revenue declines. In addition, Pfizer's pipeline looks promising with 115 programs in ...

The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

largely on the promise of Nurtec ODT, which made almost $1.4 billion in sales in 2023 and has been predicted to have reached more than $1.8 billion last year. The drug is approved both to treat ...